NCT07038941Phase 1Completed
Phase I Clinical Trial of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial of Single and Multiple Doses of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia
In the register
This trial is not attached to a programme in the register yet. Unattached trials are kept on purpose: they are where new programmes turn up first.
What the registry records
- Status
- Completed
- Declared phase
- Phase 1
- Sponsor
- Beijing Dayspring Pharmaceutical Technology Co., Ltd
- Participants (registry)
- 44
- Start
- March 2024
- Primary completion
- June 2024
- Study completion
- June 2024
- Last registry update
- June 2025
- Countries
- China
Conditions studied: Male Pattern of Hair Loss, Androgenic Alopecia, Androgenetic Alopecia (AGA)
Interventions: CG2001, Placebo foam
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.